• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Po-05-185 prediction and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy: a danish nationwide cohort study
Hypertrophic cardiomyopathy (HCM) can be associated with serious complications such as heart failure, atrial fibrillation (AF) and sudden cardiac death. The treatment of AF in HCM patients can be challenging since AF often aggravates symptoms and increases the risk of stroke. Little is known on which factors contribute to the development of AF in these patients.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Christopher Z örner, Jannik L. Pallisgaard, Anne-Marie Schjerning, Morten K. Jensen, Jacob Tønnesen, Lise D. Vestergaard, Peter Vibe Rasmussen, Gunnar Gislason, Morten L. Hansen Source Type: research

Po-01-108 elucidating the mechanism of atrial fibrillation in lamin a/c heart disease using human ipsc-derived atrial cardiomyocytes
Mutations in the LMNA gene, encoding the nuclear envelope proteins lamin A/C, cause cardiac arrhythmias, conduction disease, and dilated cardiomyopathy. Malignant arrhythmias such as atrial fibrillation (AF) and ventricular tachycardia are common and pose an increased risk of stroke and sudden cardiac death.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: William Janes, Asia Owais, Hanna Chen, Yining Chen, Michael Hill, Dawood Darbar, Srinath Yeshwant Source Type: research

Po-05-169 ventricular scar by cardiac mri is a predictor of atrial fibrillation in hypertrophic cardiomyopathy
Atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM) increases risk of stroke and mortality. The reported prevalence of AF in HCM ranges from 18% to 28%, which is higher than the general population; even after accounting for traditional risk factors including obesity, hypertension, and age. Several factors increase risk of AF in HCM including left atrial size and the presence of ventricular obstruction. However, there is paucity of data correlating ventricular late gadolinium enhancement (LGE) to the incidence of AF in HCM.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Joseph Banno, David Fermin, Dana Marsy, Nabin Manandhar Shrestha, Richard McNamara, Jeffrey Decker, Alfred J. Albano, Jose Tan, Laura Franey, Wissam Abdallah, Christopher Madison, Renzo Loyaga Rendon, Nagib T. Chalfoun Source Type: research

Po-05-141 association of interatrial block and the development of atrial fibrillation among patients with hypertrophic cardiomyopathy
Atrial fibrillation (AF) is the most common sustained arrhythmia among those with hypertrophic cardiomyopathy (HCM), affecting 1 in 5 patients. The combination of HCM and AF is associated with an increased risk of stroke, heart failure, and mortality. Interatrial block (IAB) is a distinct electrocardiographic (ECG) pattern describing conduction delay between the right and left atria through Bachmann ’s bundle. IAB has been identified as a predictor of AF across several disease states including congestive heart failure, valvular disease, and cardiac amyloidosis.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Abdullah Alissa, Nadia Bokhari, Munther K. Homoud, Ethan Rowin, Martin S. Maron, Christopher Madias Source Type: research

En-571-02 screening for putative pathogenic variants in dilated cardiomyopathy genes identifies early disease and predicts mortality
Dilated cardiomyopathy (DCM) can present with the sentinel event of sudden cardiac death, as well as heart failure, ECG abnormalities, atrial fibrillation or stroke. Data are limited regarding genetic screening and the mortality associated with DCM in a general population.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Ravi Shah, Babken Asatryan, Ghaith Sharaf Dabbagh, Mohammed Khanji, Stefan van Duijvenboden, Daniele Muser, Andrew Paul Landstrom, Christopher Semsarian, Virend Somers, Patricia B. Munroe, Anwar A. Chahal Source Type: research

Anticoagulation for Stroke Prevention in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review
Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy with a prevalence and incidence of 23% and 3.1% respectively. The risk of thromboembolism is high in patients with hypertrophic cardiomyopathy regardless of the CHADS2VASC score. This review includes five observational studies that focused on prevention of thromboembolism in patients with hypertrophic cardiomyopathy and atrial fibrillation. These papers evaluated and compared outcomes between patients on either warfarin or direct oral anticoagulants.
Source: Heart Rhythm - October 2, 2020 Category: Cardiology Authors: M. Farhan Nasser, Sanjay Gandhi, Robert J. Siegel, Florian Rader Source Type: research

Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Source Type: research

Author's reply to Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Dr. Joung and colleagues for their interests in our work.1 In our study, patients with non-valvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than NVAF patients without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study of Jung et al.,2 the stroke risk in NVAF with HCM without any other stroke risk factor was greater than that in NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all NVAF patients with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

To the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Because of high thromboembolic risk, lifelong oral anticoagulation is recommended in all patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM).1 –3 We read with great interest the article by Tsuda et al,4 who rightly emphasized the importance of HCM in thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Tags: Letter to the Editor Source Type: research

Reply to the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Joung et  al for their interest in our work.1 In our study, patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than did patients with NVAF without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study by Jung et  al,2 stroke risk in patients with NVAF with HCM without any other stroke risk factor was higher than that in patients with NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all patients with NVAF with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

Pacing for treatment and prevention of atrial fibrillation: Is there an end to this story?Editorial Commentary
Pacemakers are frequently implanted in patients with atrial fibrillation (AF), which is the most common sustained cardiac arrhythmia with causal association with stroke, heart failure, cardiomyopathy, and all-cause mortality.1–5 In a general pacemaker population, AF can also develop frequently and progressively over time.6 Thus, as no surprise, the story of “pacing and AF” has been going around for a long time.1–7 The article by Padeletti et al8 in this issue of HeartRhythm perhaps adds a new twist.
Source: Heart Rhythm - May 5, 2015 Category: Cardiology Authors: Bharat K. Kantharia Tags: Editorial Commentary Source Type: research

Patients treated with catheter ablation for ventricular tachycardia after an ICD shock have lower long-term rates of death and heart failure hospitalization than do patients treated with medical management only
Background: Ventricular arrhythmias in patients with implantable cardioverter-defibrillators (ICDs) adversely affect outcomes. Antiarrhythmic approaches to ventricular tachycardia (VT) have variable efficacy and may increase risk of ventricular arrhythmias, worsening cardiomyopathy, and death. Comparatively, VT ablation is an alternative approach that may favorably affect outcomes.Objective: To further explore the effect on long-term outcomes after catheter ablation of VT, we compared patients with history of ICD shocks who did not undergo ablation, patients with a history of ICD shocks that underwent ablation, and patient...
Source: Heart Rhythm - December 12, 2013 Category: Cardiology Authors: T. Jared Bunch, J. Peter Weiss, Brian G. Crandall, John D. Day, Heidi T. May, Tami L. Bair, Jeffrey S. Osborn, Charles Mallender, Avi Fischer, Kyle J. Brunner, Srijoy Mahapatra Tags: Ventricular Tachycardia Source Type: research